| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.
|
JAMA
|
2003
|
97.28
|
|
2
|
Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.
|
Hypertension
|
2003
|
63.78
|
|
3
|
Effects of intensive glucose lowering in type 2 diabetes.
|
N Engl J Med
|
2008
|
47.90
|
|
4
|
Effects of intensive blood-pressure control in type 2 diabetes mellitus.
|
N Engl J Med
|
2010
|
21.49
|
|
5
|
A Randomized Trial of Intensive versus Standard Blood-Pressure Control.
|
N Engl J Med
|
2015
|
19.14
|
|
6
|
Effects of combination lipid therapy in type 2 diabetes mellitus.
|
N Engl J Med
|
2010
|
16.40
|
|
7
|
Effects of medical therapies on retinopathy progression in type 2 diabetes.
|
N Engl J Med
|
2010
|
10.75
|
|
8
|
Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods.
|
Am J Cardiol
|
2007
|
9.62
|
|
9
|
Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial.
|
Lancet
|
2010
|
9.20
|
|
10
|
Alogliptin after acute coronary syndrome in patients with type 2 diabetes.
|
N Engl J Med
|
2013
|
8.74
|
|
11
|
Long-term effects of intensive glucose lowering on cardiovascular outcomes.
|
N Engl J Med
|
2011
|
8.14
|
|
12
|
Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research.
|
Hypertension
|
2008
|
6.96
|
|
13
|
Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT).
|
J Clin Hypertens (Greenwich)
|
2002
|
6.03
|
|
14
|
Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research.
|
Circulation
|
2008
|
5.26
|
|
15
|
Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.
|
Am J Cardiol
|
2007
|
4.21
|
|
16
|
Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril.
|
JAMA
|
2005
|
3.89
|
|
17
|
Blood pressure and mortality in U.S. veterans with chronic kidney disease: a cohort study.
|
Ann Intern Med
|
2013
|
2.74
|
|
18
|
Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial.
|
Circulation
|
2008
|
2.51
|
|
19
|
Visit-to-Visit Variability of Blood Pressure and Coronary Heart Disease, Stroke, Heart Failure, and Mortality: A Cohort Study.
|
Ann Intern Med
|
2015
|
2.42
|
|
20
|
Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trial.
|
Hypertension
|
2012
|
2.42
|
|
21
|
Diabetes and hypertension: the bad companions.
|
Lancet
|
2012
|
2.10
|
|
22
|
ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses.
|
Arch Intern Med
|
2009
|
2.02
|
|
23
|
Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
|
Arch Intern Med
|
2005
|
1.99
|
|
24
|
Antihypertensive prescriptions for newly treated patients before and after the main antihypertensive and lipid-lowering treatment to prevent heart attack trial results and seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure guidelines.
|
Hypertension
|
2009
|
1.92
|
|
25
|
Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients.
|
Kidney Int
|
2011
|
1.91
|
|
26
|
Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial.
|
Hypertension
|
2006
|
1.73
|
|
27
|
Effects of randomization to intensive glucose control on adverse events, cardiovascular disease, and mortality in older versus younger adults in the ACCORD Trial.
|
Diabetes Care
|
2013
|
1.71
|
|
28
|
Impact of the ALLHAT/JNC7 Dissemination Project on thiazide-type diuretic use.
|
Arch Intern Med
|
2010
|
1.64
|
|
29
|
Long-term effects of incident diabetes mellitus on cardiovascular outcomes in people treated for hypertension: the ALLHAT Diabetes Extension Study.
|
Circ Cardiovasc Qual Outcomes
|
2012
|
1.59
|
|
30
|
Antihypertensive medication adherence, ambulatory visits, and risk of stroke and death.
|
J Gen Intern Med
|
2010
|
1.57
|
|
31
|
Intensive blood pressure treatment does not improve cardiovascular outcomes in centrally obese hypertensive individuals with diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Blood Pressure Trial.
|
Diabetes Care
|
2012
|
1.55
|
|
32
|
Long-term follow-up of participants with heart failure in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT).
|
Circulation
|
2011
|
1.52
|
|
33
|
Thiazide-induced dysglycemia: call for research from a working group from the national heart, lung, and blood institute.
|
Hypertension
|
2008
|
1.46
|
|
34
|
Impact of Non-Adherence on Renal and Cardiovascular Outcomes in US Veterans.
|
Am J Nephrol
|
2015
|
1.42
|
|
35
|
Hypertension and heart failure. Roundtable discussion.
|
J Clin Hypertens (Greenwich)
|
2004
|
1.38
|
|
36
|
The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure Validation Study: diagnosis and prognosis.
|
Am Heart J
|
2007
|
1.33
|
|
37
|
Validation of Heart Failure Events in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Participants Assigned to Doxazosin and Chlorthalidone.
|
Curr Control Trials Cardiovasc Med
|
2002
|
1.13
|
|
38
|
Disparity implications of Medicare eligibility criteria for medication therapy management services.
|
Health Serv Res
|
2010
|
1.09
|
|
39
|
The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial.
|
J Clin Hypertens (Greenwich)
|
2005
|
1.02
|
|
40
|
Hypertension in adults across age groups.
|
JAMA
|
2005
|
0.96
|
|
41
|
Blood pressure-lowering efficacy of the fixed-dose combination of azilsartan medoxomil and chlorthalidone: a factorial study.
|
J Clin Hypertens (Greenwich)
|
2012
|
0.95
|
|
42
|
Hypertension control among newly treated patients before and after publication of the main ALLHAT results and JNC 7 guidelines.
|
J Clin Hypertens (Greenwich)
|
2012
|
0.95
|
|
43
|
Blood pressure control in Hispanics in the antihypertensive and lipid-lowering treatment to prevent heart attack trial.
|
Hypertension
|
2007
|
0.95
|
|
44
|
EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome.
|
Am Heart J
|
2011
|
0.94
|
|
45
|
Antihypertensive efficacy of Irbesartan/HCTZ in men and women with the metabolic syndrome and type 2 diabetes.
|
J Clin Hypertens (Greenwich)
|
2006
|
0.94
|
|
46
|
Potential health implications of racial and ethnic disparities in meeting MTM eligibility criteria.
|
Res Social Adm Pharm
|
2013
|
0.91
|
|
47
|
Antihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomil.
|
Am J Med
|
2012
|
0.91
|
|
48
|
Mortality and morbidity during and after Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: results by sex.
|
Hypertension
|
2013
|
0.90
|
|
49
|
Fosinopril versus amlodipine comparative treatments study: a randomized trial to assess effects on plasminogen activator inhibitor-1.
|
Circulation
|
2002
|
0.89
|
|
50
|
Irbesartan/HCTZ fixed combinations in patients of different racial/ethnic groups with uncontrolled systolic blood pressure on monotherapy.
|
J Natl Med Assoc
|
2006
|
0.87
|
|
51
|
Getting clinical trial results into practice: design, implementation, and process evaluation of the ALLHAT Dissemination Project.
|
Clin Trials
|
2009
|
0.86
|
|
52
|
Chlorthalidone versus hydrochlorothiazide.
|
Ann Intern Med
|
2013
|
0.86
|
|
53
|
Response to six classes of antihypertensive medications by body mass index in a randomized controlled trial.
|
J Clin Hypertens (Greenwich)
|
2003
|
0.84
|
|
54
|
New recommendations for treating hypertension in black patients: evidence and/or consensus?
|
Hypertension
|
2010
|
0.83
|
|
55
|
Diabetes clinical trials: helped or hindered by the current shift in regulatory requirements?
|
Eur Heart J
|
2012
|
0.83
|
|
56
|
National utilization of antihypertensive medications from 2000 to 2006 in the Veterans Health Administration: focus on thiazide diuretics.
|
J Clin Hypertens (Greenwich)
|
2008
|
0.82
|
|
57
|
Potential Health Implications of Medication Therapy Management Eligibility Criteria in the Patient Protection and Affordable Care Act Across Racial and Ethnic Groups.
|
J Manag Care Spec Pharm
|
2015
|
0.77
|
|
58
|
Treating systolic hypertension in the very elderly with valsartan-hydrochlorothiazide vs. either monotherapy: ValVET primary results.
|
J Clin Hypertens (Greenwich)
|
2011
|
0.77
|
|
59
|
ACC/AHA Special Report: Clinical Practice Guideline Implementation Strategies: A Summary of Systematic Reviews by the NHLBI Implementation Science Work Group: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
|
J Am Coll Cardiol
|
2017
|
0.76
|
|
60
|
The treatment of hypertension in the elderly.
|
J Clin Hypertens (Greenwich)
|
2008
|
0.76
|
|
61
|
Systolic hypertension in the elderly.
|
Postgrad Med
|
1993
|
0.75
|
|
62
|
Control of blood pressure: does it matter which agent you use?
|
J Clin Hypertens (Greenwich)
|
2007
|
0.75
|
|
63
|
Antihypertensive response to thiazide diuretic or angiotensin receptor blocker in elderly hypertensives is not influenced by pretreatment plasma renin activity.
|
Cardiovasc Drugs Ther
|
2012
|
0.75
|
|
64
|
Effect of valsartan, hydrochlorothiazide, and their combination on 24-h ambulatory blood pressure response in elderly patients with systolic hypertension: a ValVET substudy.
|
Blood Press Monit
|
2011
|
0.75
|
|
65
|
Descriptive characteristics and cluster analysis of male veteran hazardous drinkers in an alcohol moderation intervention.
|
Am J Addict
|
2012
|
0.75
|
|
66
|
How much effect of different antihypertensive medications on cardiovascular outcomes is attributable to their effects on blood pressure?
|
Stat Med
|
2012
|
0.75
|
|
67
|
Association between chronic kidney disease and cancer mortality: A report from the ALLHAT.
|
Clin Nephrol
|
2016
|
0.75
|
|
68
|
Cardiovascular Outcomes in Action to Control Cardiovascular Risk in Diabetes: Impact of Blood Pressure Level and Presence of Kidney Disease.
|
Am J Nephrol
|
2016
|
0.75
|
|
69
|
What should our blood pressure goal be in patients with diabetes?
|
J Clin Hypertens (Greenwich)
|
2007
|
0.75
|